Logo

AutoGenomics

Nov 08, 2006
Premium
AutoGenomics announced Nov. 2 the release of a series of pharmacogenetic ASRs, including CYP 450 2C9 / VKORC1, which can be used to assess warfarin sensitivity.
 
Other applications for the new ASRs include CYP 450 2D6, 2C19, NAT2, UGT1A1, MDR1 and 3A4/3A5 tests.
 
AutoGenomics CEO Fareed Kureshy touted the achievement as “the most comprehensive panel of ASRs made available by any company” and said the achievement positioned the company as a leader in personalized medicine.
 

The company has also submitted a 510(k) application for an automated multiplexing microarray platform that can provide amplified samples to test results without manual intervention by the operator.

Filed under

Diagnostics
Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.